Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Michelangelo Fiorentino
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Michelangelo Fiorentino wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review. 2016

Farina, Eleonora / Monari, Fabio / Tallini, Giovanni / Repaci, Andrea / Mazzarotto, Renzo / Giunchi, Francesca / Panzacchi, Riccardo / Cammelli, Silvia / Padula, Gilbert D A / Deodato, Francesco / Pasquali, Renato / Fanti, Stefano / Fiorentino, Michelangelo / Morganti, Alessio G. ·Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40135, Bologna, Italy. · Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40135, Bologna, Italy. rt.unibo@gmail.com. · Anatomic Pathology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Bellaria Hospital, University of Bologna, Via Altura 3, 40139, Bologna, Italy. · Division of Endocrinology, University of Bologna, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40135, Bologna, Italy. · Radiotherapy Unit, Azienda Ospedaliera Universitaria Integrata, Ospedale Civile Maggiore, Piazzale Aristide Stefani 1, Verona, Italy. · Pathology Unit of the "F. Addarii" Institute of Oncology, Department of Oncology and Hematology, University of Bologna, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40135, Bologna, Italy. · Department of Pathology, University of Bologna, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40135, Bologna, Italy. · Radiation Oncology Department, The Lacks Cancer Center, Saint Mary's Health Care, 250 Cherry St SE, Grand Rapids, MI, 49503, USA. · Radiation Oncology Unit, Fondazione "Giovanni Paolo II", Catholic University of Sacred Heart, Largo Agostino Gemelli, 1, 86100, Campobasso, Italy. · Nuclear Medicine Unit, University of Bologna, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40135, Bologna, Italy. ·Endocr Pathol · Pubmed #26662609.

ABSTRACT: The most common sites of metastatic differentiated thyroid cancer are the neck lymph nodes, while distant metastases typically involve the lungs, the bones, and less frequently the brain. Uncommon metastatic sites include the liver, adrenal gland, kidney, pancreas, and skin. The epidemiological aspects of thyroid metastases in rare sites are largely unknown and their identification could have a significant impact on patients management. A mini-series of unusual metastatic sites of thyroid carcinoma is proposed as a contribution to current knowledge on anatomopathological characteristics and clinical outcome. Of the six cases that were assessed, the metastases were the following: skin metastases (2), skin and pancreas metastases (1), renal metastasis (1), adrenal metastasis (1), and liver metastasis (1). In our experience, metastases in rare sites do not always represent a negative prognostic factor for disease outcome. In fact they can occur as single distant lesion and if surgically resectable, their treatment can also lead to local disease remission.

2 Article Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. 2018

Campana, Davide / Walter, Thomas / Pusceddu, Sara / Gelsomino, Fabio / Graillot, Emmanuelle / Prinzi, Natalie / Spallanzani, Andrea / Fiorentino, Michelangelo / Barritault, Marc / Dall'Olio, Filippo / Brighi, Nicole / Biasco, Guido. ·Department of Medical and Surgical Sciences, S.Orsola-Malpighi University Hospital, Bologna, Italy. davide.campana@unibo.it. · Hospices Civils de Lyon, University Hospital of Lyon, Lyon, France. · Department of Medical Oncology, ENETS Center of Excellence, Fondazione IRCCS 'Istituto Nazionale dei Tumori', Milan, Italy. · Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy. · Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, Bologna, Italy. ·Endocrine · Pubmed #29150792.

ABSTRACT: PURPOSE: Temozolomide (TEM) based therapy has been reported being effective in the treatment of metastatic neuroendocrine neoplasms (NEN), with response rates ranging from 30 to 70%. Among patients affected by advanced glioblastoma or melanoma and treated with TEM, loss of tumoral O6-methylguanine DNA methyltransferase (MGMT) is correlated with improved survival. In NEN patients, the role of MGMT deficiency in predicting clinical outcomes of TEM treatment is still under debate. METHODS: In this study we evaluated 95 patients with advanced NENs undergoing treatment with TEM-based therapy. MGMT promoter methylation status was evaluated with two techniques: methylation specific-polymerase chain reaction or pyrosequencing. RESULTS: Treatment with TEM-based therapy was associated with an overall response rate of 27.4% according to RECIST criteria (51.8% of patients with and 17.7% without MGMT promoter methylation). Response to therapy, progression free survival and overall survival was correlated to MGMT status at univariate and multivariate analysis. Methylation of MGMT promoter could be a strong predictive factor of objective response and an important prognostic factor of a longer PFS and OS. CONCLUSION: According to our results, MGMT methylation status, evaluated with methylation specific-polymerase chain reaction or pyrosequencing, should have an important role in patients with metastatic NENs, in order to guide therapeutic options. These results need further confirmation with prospective studies.